Zehra Ali Yılmaz

Dr. Zehra Ali Yılmaz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
HGHuri Güvey
Huri Güvey
SÇSamettin Çelik
Samettin Çelik
Canan Soyer caliskanCanan Soyer caliskan
Canan Soyer caliskan
ZYZehra Ali Yılmaz
Zehra Ali Yılmaz
MYMerve Yılmaz
Merve Yılmaz
ANDREA TINELLIANDREA TINELLI
ANDREA TINELLI
We investigated the question of how serum zonulin levels change in intrahepatic cholestasis of pregnancy (ICP) and gestational diabetes mellitus (GDM) and, in the case of the coexistence of ICP and GDM, evaluated the eventual increase in zonulin plasmatic levels. Participants were enrolled for the study between 25 February 2021 and 20 August 2021. The prospective case-control study included: group 1 of 95 pregnant women diagnosed with ICP; group 2 of 110 pregnant women diagnosed with GDM; group 3 of 16 women diagnosed with both GDM and ICP; group 4 of 136 healthy pregnant women as the control group. The groups were compared in terms of age, body mass index (BMI), gravidity, parity, gestational week of delivery, plasma zonulin levels, delivery type, birth weight, first- and fifth-minute APGAR scores, newborn intensive care unit (NICU) admission, and meconium staining of amniotic fluid parameters. The results suggested that the plasma zonulin levels of ICP (group 1), GDM (group 2), and GDM with ICP (group 3) patients were higher than those of the healthy pregnant women of group 4 (p < 0.001). Among the patient groups, the highest median plasma zonulin levels were found in group 3 (110.33 ng/mL). Zonulin levels were also associated with the severity of ICP and adverse pregnancy outcomes. High serum zonulin levels were related to GDM, ICP, and adverse perinatal outcomes. The coexistence of GDM and ICP led to higher serum zonulin concentrations.

Verified
Journal Article
Open access
PDF file
ZYZehra Ali Yılmaz
Zehra Ali Yılmaz
Nazan YurtcuNazan Yurtcu
Nazan Yurtcu
DKDilay Karademir
Dilay Karademir
Canan Soyer caliskanCanan Soyer caliskan
Canan Soyer caliskan
SCSamettin Celik
Samettin Celik
Objective: Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity; however, reliable first-trimester biomarkers are limited. Growth arrest-specific protein 6 (Gas6), a vitamin K-dependent ligand for the TAM receptor family (Tyro3, AXL, and MerTK), is crucial for trophoblast invasion and placental remodeling. This study evaluated whether first-trimester serum Gas6 levels differed between women with PE and controls and assessed the predictive utility across phenotypes. Methods: Participants were enrolled prospectively during routine first-trimester screening at 11 + 0 to 13 + 6 weeks, and cases and controls were selected using a nested case–control design after pregnancy outcomes were known. ROC-derived cut-off values for Gas6 were selected retrospectively using the Youden index and were considered exploratory. The PE group was divided into early (n = 15, <34 weeks) and late onset (n = 65, ≥34 weeks) subgroups. ELISA measured serum Gas6. Mann–Whitney U, Kruskal–Wallis, Spearman’s correlation, ROC analysis, and multivariate logistic regression were applied. Results: Gas6 levels were significantly lower in PE than controls (15.73 vs. 38.08 ng/mL, p < 0.001); control reference median (38.08 ng/mL, IQR 27.62 to 49.14), decreasing progressively to late (20.07 ng/mL) and early onset PE (6.45 ng/mL; all p < 0.001). ROC analysis showed the highest exploratory discrimination for early onset preeclampsia (AUC = 0.959, 95% CI: 0.923–0.995; sensitivity 93.3%, specificity 84.1% at a retrospectively selected cut-off of ≤13.82 ng/mL), with more modest discrimination for overall PE (AUC = 0.762) and late onset PE (AUC = 0.708). Lower first-trimester Gas6 levels remained significantly associated with early onset PE after adjustment for maternal age and BMI (OR = 0.555, 95% CI: 0.412–0.748, p < 0.001). Conclusions: Serum Gas6 levels in the first trimester are lower in PE, particularly in cases of early onset disease, highlighting its potential as a candidate biomarker that requires further prospective and external validation before any screening application can be considered.

Verified
Journal Article
Open access
PDF file
AUAsiye Uzun
Asiye Uzun
IBIsmail Biyik
Ismail Biyik
ZYZehra Ali Yılmaz
Zehra Ali Yılmaz
GTGüneş Topçu
Güneş Topçu
ÜZÜmit Zeteroğlu
Ümit Zeteroğlu
ANDREA TINELLIANDREA TINELLI
ANDREA TINELLI
Objective: Rectocele is a common posterior compartment defect that may cause defecatory dysfunction and impaired sexual function, adversely affecting quality of life. Although midline rectovaginal fascia plication (MFP) is associated with favorable anatomical outcomes, its effects on female sexual function remain insufficiently explored. This study aimed to evaluate surgical outcomes and changes in female sexual function following MFP in women with symptomatic rectocele. Methods: This retrospective study included 100 women who underwent MFP for symptomatic rectocele between January 2023 and December 2024. Objective and subjective success rates were assessed using POP-Q findings and symptom resolution. Sexual function was evaluated preoperatively and at 12 months postoperatively using the Female Sexual Function Index (FSFI). Postoperative pain was assessed using the Visual Analog Scale (VAS). Results: The mean age was 45.96 ± 10.12 years, and the mean follow-up period was 14.42 ± 3.57 months. Objective success based on POP-Q findings and subjective success based on symptom improvement were 92% and 89%, respectively. Postoperative pain decreased significantly within the first postoperative week (p < 0.001). Significant improvement was observed across all FSFI domains. The mean total FSFI score increased from 10.40 ± 4.26 preoperatively to 23.60 ± 3.46 postoperatively (p < 0.0001). Conclusions: Midline rectovaginal fascia plication is a safe and effective surgical option for symptomatic rectocele, providing high anatomical success and significant improvements in female sexual function, with minimal morbidity and rapid recovery.

6 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SASakine Merve Aydın
Sakine Merve Aydın
NGNeset Gumusburun
Neset Gumusburun
NGNaziye Gurkan
Naziye Gurkan
Nazan YurtcuNazan Yurtcu
Nazan Yurtcu
Canan Soyer caliskanCanan Soyer caliskan
Canan Soyer caliskan
MYMuhammet Sahin Yılmaz
Muhammet Sahin Yılmaz
Background: The aim of this study was to evaluate the diagnostic performance of combined testicular function indices in patients with non-obstructive azoospermia and to investigate the clinical value of these indices in predicting the diagnosis of non-obstructive azoospermia and the success of testicular sperm extraction. Methods: This retrospective observational study included 224 male patients who underwent infertility assessment. The patients were classified into a normospermic group (n = 165) and a non-obstructive azoospermia group (n = 59). Serum anti-Müllerian hormone, follicle-stimulating hormone, luteinising hormone and total testosterone levels were assessed. The Testicular Function Index, the modified Testicular Function Index and the logarithmically transformed index were calculated. Patients in the non-obstructive azoospermia group underwent micro-TESE and were classified according to sperm retrieval status. Diagnostic performance was assessed using ROC analysis. Results: Among the 59 patients with non-obstructive azoospermia who underwent micro-TESE, sperm retrieval was successful in 26 patients and unsuccessful in 33 patients. In the non-obstructive azoospermia group, anti-Müllerian hormone and testosterone levels were lower, whilst follicle-stimulating hormone and luteinising hormone levels were higher (all p < 0.001). All combined indices were found to be significantly lower in the non-obstructive azoospermia group (all p < 0.001). In the ROC analysis, follicle-stimulating hormone demonstrated the highest discriminatory performance (AUC = 0.978). In the testicular sperm extraction analysis, anti-Müllerian hormone was found to be the marker with the highest performance (AUC = 0.930). Conclusions: (Follicle-stimulating hormone demonstrated the highest diagnostic performance for distinguishing non-obstructive azoospermia, whereas anti-Müllerian hormone was the strongest predictor of TESE success. Although the combined testicular function indices showed good diagnostic performance, they did not outperform these established hormonal markers and should therefore be regarded as complementary tools for the integrated assessment of testicular function. These findings should be considered exploratory and require further validation.